Trade this ETF at your broker
Index | Solactive Pharma Breakthrough Value |
Investment focus | Equity, World, Health Care |
Fund size | EUR 15 m |
Total expense ratio | 0.49% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 14.79% |
Inception/ Listing Date | 23 January 2018 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Legal & General (LGIM) |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | No ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
Pharma Mar SA | 3.23% |
InnoCare Pharma | 3.17% |
LG Chem Ltd. | 3.12% |
BeiGene Ltd. | 3.08% |
Xeris Biopharma Holdings | 3.03% |
Alnylam Pharmaceuticals | 3.01% |
Chugai Pharmaceutical Co., Ltd. | 2.99% |
Swedish Orphan Biovitrum AB | 2.90% |
Nippon Shinyaku Co., Ltd. | 2.86% |
Bristol Myers Squibb Co. | 2.81% |
Health Care | 85.74% |
Basic Materials | 3.12% |
Other | 11.14% |
Broker | Rating | Execution fee | Account fee | |
---|---|---|---|---|
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
0.00€ | 0.00€ | View offer* | ||
0.95€ 0.95% | 0.00€ |
Broker | Rating | Order fee | ETF savings plans | |
---|---|---|---|---|
0.99€ | 2593 | View offer* | ||
1.00€ | 2414 | View offer* | ||
0.00€ | 1624 | View offer* | ||
0.00€ | 1087 | View offer* | ||
0.00€ | 897 | View offer* |
YTD | +1.16% |
1 month | -4.96% |
3 months | -2.14% |
6 months | +6.08% |
1 year | +4.47% |
3 years | -17.40% |
5 years | +4.58% |
Since inception (MAX) | +18.69% |
2023 | -13.42% |
2022 | -1.53% |
2021 | +4.12% |
2020 | +16.34% |
Volatility 1 year | 14.79% |
Volatility 3 years | 16.90% |
Volatility 5 years | 19.24% |
Return per risk 1 year | 0.30 |
Return per risk 3 years | -0.36 |
Return per risk 5 years | 0.05 |
Maximum drawdown 1 year | -13.23% |
Maximum drawdown 3 years | -27.13% |
Maximum drawdown 5 years | -28.95% |
Maximum drawdown since inception | -28.95% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | ETLI | - - | - - | - |
Borsa Italiana | EUR | BIOT | BIOT IM ETLIEUIV | BIOT.MI ETLIEURINAV=SOLA | Flow Traders B.V. |
Euronext Amsterdam | EUR | BIOT | BIOT NA ETLIEUIV | GOBIOT.AS ETLIEURINAV=SOLA | Flow Traders B.V. |
London Stock Exchange | GBX | BIGT | BIGT LN NA | BIGT.L NA | Flow Traders B.V. |
London Stock Exchange | USD | BIOT | BIOT LN NA | GEBIOT.L NA | Flow Traders B.V. |
SIX Swiss Exchange | CHF | BIOT | BIOT SW ETLIEUIV | BIOTC.S ETLIEURINAV=SOLA | Flow Traders B.V. |
XETRA | EUR | ETLI | ETLI GY ETLIEUIV | ETLI.DE ETLIEURINAV=SOLA | Flow Traders B.V. |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 989 | 0.40% p.a. | Accumulating | Sampling |
L&G Healthcare Breakthrough UCITS ETF USD Acc | 60 | 0.49% p.a. | Accumulating | Full replication |
Harbor Health Care UCITS ETF Accumulating | 15 | 0.89% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 5 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |